long intergenic non-protein coding RNA 1003Genealiases: []
Q-omics provides the consensus-scored LINC01003 profile across patient tissues and cancer cell-line models. LINC01003 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01003 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, LINC01003 RNA expression shows 18,069 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, LIHC, and ACC as cancer lineages where LINC01003 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01003 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01003 survival associations across molecular data types. LINC01003 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01003 RNA expression–survival associations across cancer types. High LINC01003 expression shows favorable associations in LUAD, OV, KIRP, KIRC, UCEC and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01003 RNA expression.
This table summarizes LINC01003 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01003. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01003 shows lower tumor expression in KIRC, THCA, BRCA and LUAD and higher tumor expression in LIHC and COAD. The LIHC box plot shows higher LINC01003 RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with LINC01003 in patient tissues and cancer cell lines. In patient samples, LINC01003 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
